Alkem Misses Analyst Estimates In Fourth Quarter, Lowering Future Guidance
Key Anti-Infective Portfolio Sales Affected By Seasonality In Indian Market
Alkem has missed analyst estimates with its fourth quarter revenue results, which featured a domestic slump in the anti-infective segment, despite higher EBITDA margins.
